Targeting Ras with Macromolecules

Total Page:16

File Type:pdf, Size:1020Kb

Targeting Ras with Macromolecules Downloaded from http://perspectivesinmedicine.cshlp.org/ on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press Targeting Ras with Macromolecules Dehua Pei, Kuangyu Chen, and Hui Liao Department of Chemistry and Biochemistry, The Ohio State University, Columbus, Ohio 43210 Correspondence: [email protected] Activating Ras mutations are associated with 30% of all human cancers and the four Ras isoforms are highly attractive targets for anticancer drug discovery. However, Ras proteins are challenging targets for conventional drug discovery because they function through intracel- lular protein–protein interactions and their surfaces lack major pockets for small molecules to bind. Over the past few years, researchers have explored a variety of approaches and modalities, with the aim of specifically targeting oncogenic Ras mutants for anticancer treatment. This perspective will provide an overview of the efforts on developing “macro- molecular” inhibitors against Ras proteins, including peptides, macrocycles, antibodies, nonimmunoglobulin proteins, and nucleic acids. as is a small GTPase, acting as a molecular Mutations in K-Ras are particularly prevalent in Rswitch in many signaling pathways and some of the most deadly cancers, including pan- regulating cell proliferation, differentiation, creatic (90% prevalence), colon (35% preva- and survival, among other functions (Young lence), and lung cancers (16% prevalence). Dis- et al. 2009). Its four isoforms, H-Ras, N-Ras, ruption of Ras function genetically (i.e., by gene K-Ras4A, and K-Ras4B, are identical within mutations or small-interfering RNA [siRNA]) the amino-terminal 85 amino acids and differ inhibits the proliferation of Ras-mutant cancer primarily in the carboxyl-termini (amino acids cells and induces apoptosis, validating Ras as 165–189). Wild-type Ras oscillates between the one of the most compelling cancer drug targets inactive guanosine diphosphate (GDP)-bound (Gupta et al. 2007; Singh et al. 2009; Castellano form (Ras-GDP) and the active guanosine tri- et al. 2013; Khvalevsky et al. 2013). phosphate (GTP)-bound form (Ras-GTP) (Fig. Over the past three decades, researchers 1A). Ras-GTP interacts with and activates mul- have explored several approaches to inhibit www.perspectivesinmedicine.org tiple effector proteins, including kinases Raf and Ras function (Wang et al. 2012; Spiegel et al. phosphoinositide 3-kinase (PI3K), turning cells 2014; Stephen et al. 2014). The ideal approach on for proliferation and survival. Somatic mu- would be direct binding to the GTPase active tations at Gly-12, Gly-13, or Gln-61, which are site by a small molecule. However, this approach all located within the GTPase active site, impair was quickly found to be impractical, because GTP hydrolysis, resulting in an excessive Ras- Ras binds to GTP (and GDP) with pM affinity GTP population leading to uncontrolled cell and GTP is present in the cytosol at mM growth. Ras mutations are found in 30% of concentrations. The next-best option is to block all human cancers and are well-established can- the interaction between Ras and its partner pro- cer drivers (Prior et al. 2012; Singh et al. 2015). teins and/or its nucleotide exchange activity. Editors: Linda VanAelst, Julian Downward, and Frank McCormick Additional Perspectives on Ras and Cancer in the 21st Century available at www.perspectivesinmedicine.org Copyright # 2017 Cold Spring Harbor Laboratory Press; all rights reserved Advanced Online Article. Cite this article as Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a031476 1 Downloaded from http://perspectivesinmedicine.cshlp.org/ on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press D. Pei et al. ABSwitch I Inactive effector-binding site RAS GDP GTP GAP Nucleotide GEF Switch II hydrolysis exchange Active RAS Effector GTP (Raf/PI3K) Dimerization interface Cell proliferation/survival Figure 1. Ras structure and function. (A) Interconversion between inactive Ras-guanosine diphosphate (GDP) and active Ras-guanosine triphosphate (GTP) mediated by guanine nucleotide exchange factor (GEF) and GTPase-activating protein (GAP). The active Ras-GTP interacts with effector proteins and activates downstream cell signaling. (B) Structure of K-Ras bound with GppNp, a nonhydrolyzable analog of GTP. The switch I/II regions are shown in red, the dimerization interface in blue, and the bound nucleotide analog is shown as sticks. (Figure was recreated from PDB data [pdb5p21].) Unfortunately, Ras has been a very challenging and provides an opportunity for selective inhi- target for direct inhibition, because its surface bition of Ras-mutant cancers. Development has no obvious pocket for small molecules of direct Ras inhibitors is challenging because to bind. Consequently, most of the early efforts Ras performs its biological functions by engag- were focused on targeting the signaling steps ing in intracellular protein–protein interac- upstream or downstream of Ras. Small-molecule tions (PPIs). PPIs are in general a challenging inhibitors against the posttranslational modifi- class of drug targets for conventional small mol- cation of Ras proteins (e.g., inhibitors against ecules (defined as molecules of 500 molecular farnesyl and geranylgeranyl transferases) ulti- weight), because small molecules typically do mately proved to be ineffective clinically, because not make a sufficient number of contacts with of either a lack of efficacy or unacceptable toxic- the large flat PPI interfaces to impart high af- ity (Whyte et al. 1997; Konstantinopoulos et al. finity or specificity. To effectively compete with 2007; Berndt et al. 2011). Another indirect ap- the protein partners, a PPI inhibitor should also www.perspectivesinmedicine.org proach is inhibition of the protein kinases down- possess a binding surface comparable in size to stream of Ras. Several MEK and PI3K inhibitors that of the partner proteins. Recognizing this, are currently undergoing clinical evaluation, al- researchers have increasingly turned their atten- though the clinical effectiveness of this approach tion to larger molecules, including peptides, remains to be seen (Engelman et al. 2008). It macrocycles, and proteins, as PPI inhibitors. appears that simultaneous inhibition of at least Powerful combinatorial library technologies two different pathways (e.g., by both MEK and for discovering peptide—especially macrocyclic PI3K inhibitors) is necessary to effectively block peptide—ligands and novel approaches to Ras signaling in Ras-mutant tumors (Britten improving their membrane permeability have et al. 2013); however, blocking multiple signal- recently been developed (Dougherty et al. ing pathways may result in extensive toxicity. 2017). Application of these technologies to Driven by both urgent unmet medical needs Ras has resulted in a variety of Ras inhibitors, and remarkable technological breakthroughs, ranging from small molecules, peptides, macro- there has been a recent “renaissance” of the di- cycles, proteins, to nucleic acids over the past rect Ras inhibition approach (Ledford 2015), few years (Fig. 2). In this review, we provide a which attacks Ras-driven cancers at the source summary of the “macromolecular” approaches 2 Advanced Online Article. Cite this article as Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a031476 Downloaded from http://perspectivesinmedicine.cshlp.org/ on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press Macromolecular Ras Inhibitors A B O O OONH2 O H H H CI OH N N N N RRFFGI N N LKTEEGN-NH2 N H H I N OO H OH O C D NH2 F N H2N O O H O N NH NH2 O N NH H O O O NH NH O H O N O N H O H N NH N H N N O H H2N OH N N NH NH2 2 H N 2 NH2 NH2 EFG VH VL www.perspectivesinmedicine.org Figure 2. Molecular modalities that have been used as direct Ras inhibitors. (A) Small molecules (example shown is the K-RasG12C-selective inhibitor by Ostrem et al. 2013); (B) stapled peptides (example shown is SAH-SOS1); (C) macrocyclic peptides (example shown is cyclorasin 9A5); (D) monoclonal antibodies; (E) intrabodies (the VH and VL regions of an antibody linked by a polypeptide or disulfide bond); (F) affibodies; and (G) monobodies (the tenth fibronectin type III domain of human fibronectin). to Ras inhibitor development (as opposed to quences of several Ras effector proteins and the small-molecule approach). For an updated identified a consensus Ras-binding sequence account on small-molecule Ras inhibitors, shared among a subset of the Ras effectors. readers are referred to Zhou et al. (2017). They showed that peptides containing this se- quence from Raf-1 (Table 1, compound 1) and PEPTIDE-BASED INHIBITORS NF1-GAP (Table 1, compound 2) blocked NF1- GAP stimulation of Ras GTPase activity and Linear Peptides Ras-mediated activation of mitogen-activated The first peptidyl Ras inhibitors were discovered protein kinases, with IC50 values of 45 mM. by Clark et al. (1996), who compared the se- Similarly, Barnard et al. (1998) systematically Advanced Online Article. Cite this article as Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a031476 3 Downloaded from http://perspectivesinmedicine.cshlp.org/ on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press D. Pei et al. tested short peptides corresponding to different cell-permeable and reduced epidermal growth regions of H-Ras and Raf-1 for in vitro inhibi- factor (EGF)-stimulated Ras activation and tion of the Ras-Raf association and found that downstream signaling events in HeLa cells. two of the Raf-1 peptides, E94CCAVFR100 (Table More recently, Leshchiner et al. (2015) designed 1, compound 3) and C95CAVFRL101 (Table 1, a hydrocarbon-stapled a-helical peptide with compound 4), were significant inhibitors of much greater Ras-binding affinity, SAH-SOS1 95 101 Ras-Raf binding. Peptide C CAVFRL had (KD ,200 nM) (Table 1, compound 9 and an IC50 value of 7 mM and also inhibited Ras- Fig. 2B), also corresponding to the Ras-binding RalGDS binding. Xu and Luo (2002) screened helical motif in SOS. SAH-SOS1 was insensitive 3.5 Â 107 peptide aptamers and isolated two to the nucleotide-bound states of Ras.
Recommended publications
  • Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases
    Antibodies 2015, 4, 170-196; doi:10.3390/antib4030170 OPEN ACCESS antibodies ISSN 2073-4468 www.mdpi.com/journal/antibodies Review Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases Marta Westwood * and Alastair D. G. Lawson Structural Biology, UCB, 216 Bath Road, Slough, SL1 3WE UK; E-Mail: [email protected]. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +44-1-753-534-655 (ext.7749); Fax: +44-1-753-536-632. Academic Editor: Dimiter S. Dimitrov Received: 13 May 2015 / Accepted: 9 July 2015 / Published: 15 July 2015 Abstract: Assembly of misfolded proteins into fibrillar deposits is a common feature of many neurodegenerative diseases. Developing effective therapies to these complex, and not yet fully understood diseases is currently one of the greatest medical challenges facing society. Slow and initially asymptomatic onset of neurodegenerative disorders requires profound understanding of the processes occurring at early stages of the disease including identification and structural characterisation of initial toxic species underlying neurodegeneration. In this review, we chart the latest progress made towards understanding the multifactorial process leading to amyloid formation and highlight efforts made in the development of therapeutic antibodies for the treatment of amyloid-based disorders. The specificity and selectivity of conformational antibodies make them attractive research probes to differentiate between transient states preceding formation of mature fibrils and enable strategies for potential therapeutic intervention to be considered. Keywords: antibody; amyloids; conformation; prion; Alzheimer’s; Parkinson’s; fibrils, tau; Huntingtin; protein misfolding 1. Introduction Correct protein folding is crucial for maintaining healthy biological functions.
    [Show full text]
  • Rapid Selection of Specific MAP Kinase-Binders from Designed Ankyrin Repeat Protein Libraries
    Protein Engineering, Design & Selection vol. 19 no. 5 pp. 219–229, 2006 Published online March 21, 2006 doi:10.1093/protein/gzl004 Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries Patrick Amstutz1,4,5, Holger Koch1,4, H. Kaspar Binz1, form in this milieu. For this reason, antibodies were Stefan A. Deuber2 and Andreas Plu¨ckthun1,3 engineered for higher intracellular stability with some success 1 et al ¨ ¨ Biochemisches Institut der Universita¨tZu¨rich, Winterthurerstrasse 190, (Proba ., 1998; Worn and Pluckthun, 1998; Desiderio CH-8057 Zu¨rich, Switzerland and 2Institut fu¨r Medizinische Virologie der et al., 2001; Visintin et al., 2002), but the number of selected Universita¨tZu¨rich, Gloriastrasse 30, Zu¨rich, Switzerland and active binders is usually limited (Tanaka and Rabbitts, 3To whom correspondence should be addressed. 2003; Koch et al., 2006). These results can be explained by E-mail: [email protected] the selection pressure, which not only places demands on 4These authors contributed equally to this work. 5 specific binding but also requires stability under reducing Present address: Molecular Partners AG, c/o Universita¨tZu¨rich, conditions. Winterthurerstrasse 190, CH-8057 Zu¨rich, Switzerland To overcome these limitations of immunoglobulin We describe here the rapid selection of specific MAP-kinase domains, a variety of novel scaffolds for the generation of binders from a combinatorial library of designed ankyrin antibody-like binding molecules, some of them possessing repeat proteins (DARPins). A combined in vitro/in vivo selec- very favorable biophysical properties, has been developed tion approach, based on ribosome display and the protein (Nygren and Skerra, 2004; Binz et al., 2005).
    [Show full text]
  • Nanobodies Right in the Middle: Intrabodies As Toolbox to Visualize and Modulate Antigens in the Living Cell
    biomolecules Review Nanobodies Right in the Middle: Intrabodies as Toolbox to Visualize and Modulate Antigens in the Living Cell Teresa R. Wagner 1,2 and Ulrich Rothbauer 1,2,* 1 Pharmaceutical Biotechnology, Eberhard Karls University Tuebingen, 72076 Tuebingen, Germany; [email protected] 2 Natural and Medical Sciences Institute, University of Tuebingen, 72770 Reutlingen, Germany * Correspondence: [email protected]; Tel.: +49-7121-5153-0415; Fax: +49-7121-5153-0816 Received: 30 November 2020; Accepted: 18 December 2020; Published: 21 December 2020 Abstract: In biomedical research, there is an ongoing demand for new technologies to elucidate disease mechanisms and develop novel therapeutics. This requires comprehensive understanding of cellular processes and their pathophysiology based on reliable information on abundance, localization, post-translational modifications and dynamic interactions of cellular components. Traceable intracellular binding molecules provide new opportunities for real-time cellular diagnostics. Most prominently, intrabodies derived from antibody fragments of heavy-chain only antibodies of camelids (nanobodies) have emerged as highly versatile and attractive probes to study and manipulate antigens within the context of living cells. In this review, we provide an overview on the selection, delivery and usage of intrabodies to visualize and monitor cellular antigens in living cells and organisms. Additionally, we summarize recent advances in the development of intrabodies as cellular biosensors and their application to manipulate disease-related cellular processes. Finally, we highlight switchable intrabodies, which open entirely new possibilities for real-time cell-based diagnostics including live-cell imaging, target validation and generation of precisely controllable binding reagents for future therapeutic applications. Keywords: nanobody; intrabody; phage display; live-cell imaging; biosensors; target validation 1.
    [Show full text]
  • Designer Oncolytic Adenovirus: Coming of Age
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 21 May 2018 doi:10.20944/preprints201805.0273.v1 Designer Oncolytic Adenovirus: Coming of Age Alexander T. Baker1, Carmen Aguirre-Hernandez2, Gunnel Hallden2, Alan L. Parker1* 1 Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, CF14 4XN, United Kingdom 2 Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, EC1M 6BQ, United Kingdom *Corresponding author Dr. Alan L. Parker Division of Cancer and Genetics Henry Wellcome Building Cardiff University School of Medicine Heath Park Cardiff CF14 4XN Email: [email protected] Keywords: adenovirus; oncolytic; targeting; virotherapy; cancer; αvβ6 integrin; immunotherapy; tropism 1 © 2018 by the author(s). Distributed under a Creative Commons CC BY license. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 21 May 2018 doi:10.20944/preprints201805.0273.v1 Contents 1. Introduction: ................................................................................................................................... 4 2. Replication-selective adenoviruses ..................................................................................................... 6 2.1 Combination of oncolytic adenoviruses with chemotherapy ..................................................... 11 3. Oncolytic immunotherapy ................................................................................................................ 12 4. Tropism modification strategies ......................................................................................................
    [Show full text]
  • Article in Press
    G Model MIMM-4561; No. of Pages 12 ARTICLE IN PRESS Molecular Immunology xxx (2015) xxx–xxx Contents lists available at ScienceDirect Molecular Immunology j ournal homepage: www.elsevier.com/locate/molimm Review Alternative molecular formats and therapeutic applications for ଝ bispecific antibodies ∗ Christoph Spiess, Qianting Zhai, Paul J. Carter Department of Antibody Engineering, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA a r t i c l e i n f o a b s t r a c t Article history: Bispecific antibodies are on the cusp of coming of age as therapeutics more than half a century after they Received 28 November 2014 ® were first described. Two bispecific antibodies, catumaxomab (Removab , anti-EpCAM × anti-CD3) and Received in revised form ® blinatumomab (Blincyto , anti-CD19 × anti-CD3) are approved for therapy, and >30 additional bispecific 30 December 2014 antibodies are currently in clinical development. Many of these investigational bispecific antibody drugs Accepted 2 January 2015 are designed to retarget T cells to kill tumor cells, whereas most others are intended to interact with two Available online xxx different disease mediators such as cell surface receptors, soluble ligands and other proteins. The modular architecture of antibodies has been exploited to create more than 60 different bispecific antibody formats. Keywords: These formats vary in many ways including their molecular weight, number of antigen-binding sites, Bispecific antibodies spatial relationship between different binding sites, valency for each antigen, ability to support secondary Antibody engineering Antibody therapeutics immune functions and pharmacokinetic half-life. These diverse formats provide great opportunity to tailor the design of bispecific antibodies to match the proposed mechanisms of action and the intended clinical application.
    [Show full text]
  • Strategies for Selecting Membrane Protein-Specific Antibodies Using Phage Display with Cell-Based Panning
    antibodies Review Strategies for Selecting Membrane Protein-Specific Antibodies using Phage Display with Cell-Based Panning Mohamed A. Alfaleh 1,2,* ID , Martina L. Jones 1,3,* ID , Christopher B. Howard 1,3,4 and Stephen M. Mahler 1,3 1 Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland 4072, Australia; [email protected] (C.B.H.); [email protected] (S.M.M) 2 Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia 3 Australian Research Council Training Centre for Biopharmaceutical Innovation, The University of Queensland, Brisbane, Queensland 4072, Australia 4 Centre for Advanced Imaging, The University of Queensland, Brisbane, Queensland 4072, Australia * Correspondence: [email protected] (M.A.A.); [email protected] (M.L.J.); Tel.: +61-733-463-178 (M.L.J.) Academic Editor: Dimiter S. Dimitrov Received: 14 June 2017; Accepted: 7 July 2017; Published: 5 August 2017 Abstract: Membrane proteins are attractive targets for monoclonal antibody (mAb) discovery and development. Although several approved mAbs against membrane proteins have been isolated from phage antibody libraries, the process is challenging, as it requires the presentation of a correctly folded protein to screen the antibody library. Cell-based panning could represent the optimal method for antibody discovery against membrane proteins, since it allows for presentation in their natural conformation along with the appropriate post-translational modifications. Nevertheless, screening antibodies against a desired antigen, within a selected cell line, may be difficult due to the abundance of irrelevant organic molecules, which can potentially obscure the antigen of interest.
    [Show full text]
  • A Genetically-Encoded Toolkit of Functionalized Nanobodies Against Fluorescent Proteins
    bioRxiv preprint doi: https://doi.org/10.1101/544700; this version posted April 26, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 A genetically-encoded toolkit of functionalized nanobodies against fluorescent proteins 2 for visualizing and manipulating intracellular signalling 3 4 David L. Prole1,* and Colin W. Taylor1,* 5 1Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge 6 CB2 1PD, United Kingdom 7 8 *For correspondence: [email protected], [email protected] 9 10 Short title 11 Functionalized nanobodies for studying intracellular signalling 12 13 Keywords: cell signalling, endoplasmic reticulum, fluorescence microscopy, fluorescent 14 protein, GFP, intrabody, membrane contact site, mitochondria, nanobody, RFP. 1 bioRxiv preprint doi: https://doi.org/10.1101/544700; this version posted April 26, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 15 Abbreviations 2+ 2+ 16 BFP, blue fluorescent protein; [Ca ]c, cytosolic free Ca concentration; CALI, 17 chromophore-assisted light inactivation; CaM, calmodulin; CFP, cyan fluorescent protein; 18 ER, endoplasmic reticulum; FKBP, FK506-binding protein; FRB, FKBP-rapamycin-binding 19 domain; FP, fluorescent protein; GFP, green fluorescent protein; GNb, GFP-binding 20 nanobody; HBS, HEPES-buffered saline; IP3R, inositol 1,4,5-trisphosphate receptor; 21 LAMP1, lysosomal membrane protein 1; mCherry, monomeric Cherry; MCS, membrane 22 contact site; MHBS, modified HBS; MP, multimerizing protein; mRFP, monomeric red 23 fluorescent protein; OMM, outer mitochondrial membrane; PM, plasma membrane; RFP, red 24 fluorescent protein; RNb, RFP-binding nanobody; ROI, region of interest; SOCE, store- 25 operated Ca2+ entry; TIRFM, total internal reflection fluorescence microscopy; YFP, yellow 26 fluorescent protein.
    [Show full text]
  • Advances in Targeted Degradation of Endogenous Proteins Roth, Sascha; Fulcher, Luke; Sapkota, Gopal
    University of Dundee Advances in targeted degradation of endogenous proteins Roth, Sascha; Fulcher, Luke; Sapkota, Gopal Published in: Cellular and Molecular Life Sciences DOI: 10.1007/s00018-019-03112-6 Publication date: 2019 Licence: CC BY Document Version Publisher's PDF, also known as Version of record Link to publication in Discovery Research Portal Citation for published version (APA): Roth, S., Fulcher, L., & Sapkota, G. (2019). Advances in targeted degradation of endogenous proteins. Cellular and Molecular Life Sciences, 76(14), 2761-2777. https://doi.org/10.1007/s00018-019-03112-6 General rights Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain. • You may freely distribute the URL identifying the publication in the public portal. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 29. Sep. 2021 Cellular and Molecular Life Sciences https://doi.org/10.1007/s00018-019-03112-6 Cellular andMolecular Life Sciences REVIEW Advances in targeted degradation of endogenous proteins Sascha Röth1 · Luke J. Fulcher1 · Gopal P. Sapkota1 Received: 11 January 2019 / Revised: 23 March 2019 / Accepted: 16 April 2019 © The Author(s) 2019 Abstract Protein silencing is often employed as a means to aid investigations in protein function and is increasingly desired as a thera- peutic approach.
    [Show full text]
  • PEGS Europe 2014 in Lisbon James West, Ph.D., Research Fellow, Protein Engineering, Cytomx Therapeutics, Inc
    Register by 10 October and Save up to €220 COVER Sixth Annual Final Agenda SHORT COURSES CONFERENCE AT-A-GLANCE STREAM 1: ANTIBODY ENGINEERING PHAGE & YEAST DISPLAY CONSTRUCTS & SCAFFOLDS 3-7 NOVEMBER 2014 | MARRIOTT HOTEL | LISBON, PORTUGAL CANCER BIOTHERAPEUTICS PLENARY KEYNOTES STREAM 2: The Impact of the New Regulatory Guidance Current Progress with Armed BIOLOGICS DEVELOPMENT Landscape on the Validation of the Manufacturing Antibody Products Two Consecutive Process and the Characterisation of Starting Dario Neri, Ph.D., ETH Zurich Materials, Drug Substance and Drug Product OPTIMISATION & DEVELOPMENT Years of Steffen Gross, Ph.D., Paul-Ehrlich-Institut 40% Growth in AGGREGATES & PARTICLES KEYNOTE PRESENTERS Attendance! Roslyn Bill, Aston University Birmingham Ewa Marszal, U.S. Food & Drug Administration CHARACTERISING BIOTHERAPEUTICS H. Kaspar Binz, Molecular Partners AG John McCafferty, IONTAS Ltd. STREAM 3: Klaus Bosslet, Roche Pharmaceuticals, Penzberg Jonas Schaefer, University of Zurich PROTEIN ENGINEERING Rakesh Dixit, MedImmune LLC Ralf Schumacher, Roche Penzberg & pRED Stefan Dübel, Technische Universität Braunschweig Janine Schuurman, Genmab DIFFICULT TO EXPRESS PROTEINS Jacques Dumas, sanofi Florian Wurm, Swiss Federal Institute of Technology Lausanne (EPFL) David James, University of Sheffield OPTIMISING PROTEIN EXPRESSION ANTIBODY EXPRESSION HOTEL & TRAVEL INFO SPONSORSHIP & EXHIBIT PEGSummitEurope.com ORGANIZED BY: PREMIER SPONSORS: 1 Short Courses* Maximize Your Productivity Maximize your educational and networking opportunities while in Lisbon by adding a short course. Continued training and education are essential for staying competitive. COVER These interactive short courses are a great introduction for those new to a particular discipline or as a refresher for those who want to brush up on their knowledge or expand their horizons. Attendance is limited to ensure an interactive environment.
    [Show full text]
  • Engineered Extracellular Vesicles/Exosomes As a New Tool Against Neurodegenerative Diseases
    pharmaceutics Review Engineered Extracellular Vesicles/Exosomes as a New Tool against Neurodegenerative Diseases Flavia Ferrantelli *, Chiara Chiozzini, Patrizia Leone, Francesco Manfredi and Maurizio Federico * National Center for Global Health, Istituto Superiore Di Sanità (ISS), 00161 Rome, Italy; [email protected] (C.C.); [email protected] (P.L.); [email protected] (F.M.) * Correspondence: fl[email protected] (F.F.); [email protected] (M.F.); Tel.: +39-06-4990-3212 (F.F.); +39-06-4990-3605 (M.F.) Received: 14 May 2020; Accepted: 6 June 2020; Published: 9 June 2020 Abstract: Neurodegenerative diseases are commonly generated by intracellular accumulation of misfolded/aggregated mutated proteins. These abnormal protein aggregates impair the functions of mitochondria and induce oxidative stress, thereby resulting in neuronal cell death. In turn, neuronal damage induces chronic inflammation and neurodegeneration. Thus, reducing/eliminating these abnormal protein aggregates is a priority for any anti-neurodegenerative therapeutic approach. Although several antibodies against mutated neuronal proteins have been already developed, how to efficiently deliver them inside the target cells remains an unmet issue. Extracellular vesicles/exosomes incorporating intrabodies against the pathogenic products would be a tool for innovative therapeutic approaches. In this review/perspective article, we identify and describe the major molecular targets associated with neurodegenerative diseases, as well as the antibodies already developed against them. Finally, we propose a novel targeting strategy based on the endogenous engineering of extracellular vesicles/exosomes constitutively released by cells of the central nervous system. Keywords: neurodegenerative disease therapy; extracellular vesicles/exosomes; intrabodies 1. Introduction Several neurodegenerative diseases (NDs) arise from cell degeneration induced by the accumulation of misfolded/mutated proteins.
    [Show full text]
  • Intrabodies to Their Antigen Targets
    Inducible strategies for controlling binding of intrabodies to their antigen targets Technical Journal Club 28.04.2020 Francesca Catto Paper #1 Paper #2 What are intrabodies? • Intrabodies are small format antibodies that function inside of cells - Delivered as DNA packaged in a virus - Intrabody DNA does not incorporate into cell DNA Introduction Intrabodies Produced in the cell, and bind an antigen within the same cell. Antibodies are soluble proteins that are normally found circulating the body within the serum. They are synthesized in the endoplasmic reticulum (ER) of B cells as separate heavy chain and light chains, which are then linked by disulfide bonds in the mature Ig. However, the full-length antibody is not functional in the cytosol, prior to secretion, due to its reducing conditions, which affect protein folding and the intramolecular disulfide bonds that are required to maintain the antibody’s conformation and stability. Variable regions characterize an antibody with its exceptional target specificity. --> it is possible to use antibody fragments incorporating the specificity-providing regions within a single-chain variable fragment (scFv), which can be further engineered for cytosolic stability, to target intracellular antigens Fig1 Introduction The variable (V) region domain can be used by itself to form a domain antibody or Dab. These can be engineered from conventional human Igs. Fig2a Introduction The variable (V) region domain can be used by itself to form a domain antibody or Dab. These can be engineered from conventional human Igs. Fig2a Single heavy chain V regions or light chain V regions can be expressed inside cells. These are referred to as intracellular domain antibodies, which do not require intramolecular disulfide bonds for stability, hence representing the smallest format of the antibody that retains target specificity while minimizing size.
    [Show full text]
  • A Universal Synthetic Library of Humanized Nanobodies
    TOOLS AND RESOURCES NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies Sandrine Moutel1,2,3†, Nicolas Bery4,5†, Virginie Bernard1, Laura Keller4,5,6, Emilie Lemesre1,2, Ario de Marco1, Laetitia Ligat7, Jean-Christophe Rain8, Gilles Favre4,5,6, Aure´ lien Olichon4,5*, Franck Perez1,2* 1Institut Curie, PSL Research University, Paris, France; 2CNRS UMR144, Paris, France; 3Translational Research Department, Institut Curie, Paris, France; 4Inserm, UMR 1037-CRCT, Toulouse, France; 5Faculte´ des Sciences Pharmaceutiques, Universite´ Toulouse III-Paul Sabatier, Toulouse, France; 6Institut Claudius Regaud, Toulouse, France; 7Le Poˆle Technologique du Centre de Recherches en Cance´rologie de Toulouse, plateau de prote´omique, Toulouse, France; 8Hybrigenics Service, Paris, France Abstract In vitro selection of antibodies allows to obtain highly functional binders, rapidly and at lower cost. Here, we describe the first fully synthetic phage display library of humanized llama single domain antibody (NaLi-H1: Nanobody Library Humanized 1). Based on a humanized synthetic single domain antibody (hs2dAb) scaffold optimized for intracellular stability, the highly diverse library provides high affinity binders without animal immunization. NaLi-H1 was screened following several selection schemes against various targets (Fluorescent proteins, actin, tubulin, p53, HP1). Conformation antibodies against active RHO GTPase were also obtained. Selected hs2dAb were *For correspondence: aurelien. used in various immunoassays and were often found to be functional intrabodies, enabling tracking [email protected] (AO); Franck. or inhibition of endogenous targets. Functionalization of intrabodies allowed specific protein [email protected] (FP) knockdown in living cells. Finally, direct selection against the surface of tumor cells produced hs2dAb directed against tumor-specific antigens further highlighting the potential use of this †These authors contributed library for therapeutic applications.
    [Show full text]